Hyperplasia News and Research

RSS

Pros, cons of finasteride to prevent prostate cancer should be considered

Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

22 Jan 2008

Prostatitis - one of the most common urologic diseases in the U.S

Estimates on the number of males in the United States who will experience prostatitis during their lifetimes range up to 50 percent.

21 Jan 2008

New classification system for rare lung diseases in infants

A new classification system of rare lung diseases in infants is improving diagnosis and treatment.

3 Dec 2007

Urinary complications in men over 45

As many as one in four men admitted to hospital with acute urinary retention will die within a year, finds a study published on bmj.com.

13 Nov 2007

Coping with urinary incontinence

For older adults, increased urinary frequency is fairly common.

26 Sep 2007

Barr confirms UROXATRAL patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sanofi- Aventis U.S. LLC in connection with its UROXATRAL (alfuzosin hydrochloride extended-release tablets), 10mg.

25 Sep 2007

Black men do not have more aggressive prostate cancer

A University of Minnesota study of prostate cancer tumors from Caucasian and African-American men has shown no evidence that the cancer is more aggressive in black men.

18 Sep 2007

Shrinkage of prostate led to overestimation of cancer risk in finasteride trial

Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.

13 Sep 2007

Finasteride will cause little or no sexual dysfunction for most men who decide to take it

Men and their physicians need not hesitate to use a drug proven effective in preventing prostate cancer out of concern that it is likely to cause sexual dysfunction, say authors of a study conducted by the Southwest Oncology Group.

20 Jul 2007

Genetically engineered herpes simplex virus keeps arteries free-flowing

A genetically engineered herpes simplex virus, primarily known for causing cold sores, may help keep arteries "free-flowing" in the weeks following angioplasty or stent placement for patients, according to research published early in the online edition of PNAS (Proceedings of the National Academy of Sciences of the United States of America).

11 Jul 2007

Ranbaxy receives tentative FDA approval for Tamsulosin capsules

Ranbaxy Pharmaceuticals has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg.

23 Jun 2007

Botox for enlarged prostate

Injecting botulinum toxin A, or Botox, into the prostate gland of men with enlarged prostate, eased symptoms and improved quality of life up to a year after the procedure, according to a study by researchers at the Chang Gung University Medical College, Taiwan, and the University of Pittsburgh School of Medicine.

24 May 2007

Merits and risks of postmenopausal hormone therapy

The study was categorized as a primary prevention trial for coronary heart disease, although the fact that mean age at recruitment was 63 years was not given enough importance at that time. WHI investigators concluded that hormone therapy (HT) was not cardioprotective, and, in fact, its riskbenefit ratio did not favor the use of postmenopausal hormones for prevention of chronic diseases.

17 May 2007

Regular exercise associated with reduced risk of benign prostatic hyperplasia

Protection against heart disease, stroke, diabetes, obesity, hypertension, memory loss, colon cancer, fractures, and depression should be enough to get men exercising.

4 May 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Prostate cancer treatment decisions can be complicated

For many men with early-stage prostate cancer, sorting out the treatment options can be overwhelming.

20 Apr 2007

Placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

All physicians involved in the treatment of PBS/IC understand that the placebo effect likely plays a major role in treatment, and is important when evaluating drug trials.

19 Apr 2007

Scientists gain insights into liver regeneration

The way the liver renews itself may be simpler than what scientists had been assuming.

12 Apr 2007

Decoy receptor 3 expressed in rheumatic synovial fibroblasts protects the cells against Fas-induced apoptosis

A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.

30 Mar 2007

American Cancer Society issues recommendation on MRI for breast cancer screening

An expert panel convened by the American Cancer Society has developed new recommendations for the use of magnetic resonance imaging (MRI) for women at increased risk for breast cancer, and recommends annual screening using MRI in addition to mammography for women with a 20-25 percent or greater lifetime risk of the disease.

29 Mar 2007